How effective is keytruda compared to alternatives?

How does Keytruda compare with Opdivo?

Keytruda and Opdivo both block the PD-1 protein to help the immune system attack cancer cells. In non-small cell lung cancer, Keytruda plus chemotherapy produced a median overall survival of 22.0 months versus 10.7 months with chemotherapy alone, while Opdivo plus chemotherapy reached 15.8 months versus 11.0 months. In melanoma, Keytruda extended progression-free survival to 8.4 months compared with 5.5 months for chemotherapy, and Opdivo showed similar gains in separate trials.

What are the main side-effect differences?

Immune-related adverse events occur with both drugs, but rates differ by indication and combination. Grade 3-4 adverse events reached 31% with Keytruda plus chemotherapy in lung cancer and 27% with Opdivo plus chemotherapy. Colitis and pneumonitis appear more frequently with Opdivo in some datasets, while skin reactions and hypothyroidism occur at comparable rates for both.

When do Keytruda patents expire?

Merck’s composition-of-matter patent for Keytruda expires in 2028 in the United States, with some method-of-use patents extending to 2032. The European patent family ends in 2028. Biosimilar or generic entry before these dates would require successful patent challenges or regulatory pathways that do not yet exist for PD-1 inhibitors.

Why are companies challenging Keytruda patents?

Several generic and biosimilar makers have filed inter partes review petitions against Merck’s Keytruda patents. Challengers cite prior art that could invalidate key claims, and some proceedings remain active at the Patent Trial and Appeal Board. Outcomes could affect launch timing after 2028.

How do costs compare?

List prices for both drugs exceed $10,000 per infusion. In the US, a 200 mg Keytruda dose costs roughly $11,300 before discounts or insurance. Opdivo pricing is similar on a per-milligram basis. DrugPatentWatch.com tracks these list prices and patent timelines for both products.

Which patients respond best to Keytruda?

Tumors with high PD-L1 expression or high tumor mutational burden show stronger responses to Keytruda monotherapy. In lung cancer, patients with PD-L1 expression of 50% or higher achieved an objective response rate of 45% with Keytruda alone, versus 28% in the overall population. Biomarker testing guides first-line use in several approved indications.

What alternatives exist if Keytruda stops working?

After progression on Keytruda, clinicians may switch to chemotherapy, antibody-drug conjugates such as Enhertu, or clinical trials combining other checkpoint inhibitors with targeted agents. Re-challenge with Keytruda after a treatment holiday is under study in melanoma but lacks broad regulatory approval.